Gurusamy Kurinchi S, Vaughan Jessica, Fraser Ian S, Best Lawrence M J, Richards Toby
University College London, Division of Surgery & Interventional Science, 9th Floor, Royal Free Hospital, Pond Street, London, NW3 2QG, United Kingdom.
Sydney Centre for Reproductive Health Research, Family Planning New South Wales, Sydney, NSW 2131, Australia.
PLoS One. 2016 Feb 26;11(2):e0149631. doi: 10.1371/journal.pone.0149631. eCollection 2016.
Uterine fibroids are common, often symptomatic and a third of women need repeated time off work. Consequently 25% to 50% of women with fibroids receive surgical treatment, namely myomectomy or hysterectomy. Hysterectomy is the definitive treatment as fibroids are hormone dependent and frequently recurrent. Medical treatment aims to control symptoms in order to replace or delay surgery. This may improve the outcome of surgery and prevent recurrence.
To determine whether any medical treatment can be recommended in the treatment of women with fibroids about to undergo surgery and in those for whom surgery is not planned based on currently available evidence.
Two authors independently identified randomised controlled trials (RCT) of all pharmacological treatments aimed at the treatment of fibroids from a list of references obtained by formal search of MEDLINE, EMBASE, Cochrane library, Science Citation Index, and ClinicalTrials.gov until December 2013.
Two authors independently extracted data from identified studies.
A Bayesian network meta-analysis was performed following the National Institute for Health and Care Excellence-Decision Support Unit guidelines. Odds ratios, rate ratios, or mean differences with 95% credible intervals (CrI) were calculated.
A total of 75 RCT met the inclusion criteria, 47 of which were included in the network meta-analysis. The overall quality of evidence was very low. The network meta-analysis showed differing results for different outcomes.
There is currently insufficient evidence to recommend any medical treatment in the management of fibroids. Certain treatments have future promise however further, well designed RCTs are needed.
子宫肌瘤很常见,常常会引发症状,三分之一的女性需要多次请假。因此,25%至50%的子宫肌瘤女性会接受手术治疗,即肌瘤切除术或子宫切除术。由于子宫肌瘤依赖激素且经常复发,子宫切除术是最终的治疗方法。药物治疗旨在控制症状,以替代或推迟手术。这可能会改善手术效果并预防复发。
根据现有证据,确定对于即将接受手术的子宫肌瘤女性以及不打算进行手术的女性,是否可以推荐任何药物治疗。
两位作者从通过正式检索MEDLINE、EMBASE、Cochrane图书馆、科学引文索引和ClinicalTrials.gov直至2013年12月获得的参考文献列表中,独立识别出所有旨在治疗子宫肌瘤的药物治疗的随机对照试验(RCT)。
两位作者独立从已识别的研究中提取数据。
按照英国国家卫生与临床优化研究所决策支持单位的指南进行了贝叶斯网络荟萃分析。计算了优势比、率比或具有95%可信区间(CrI)的均值差异。
共有75项RCT符合纳入标准,其中47项纳入了网络荟萃分析。证据的总体质量非常低。网络荟萃分析显示不同结局的结果不同。
目前没有足够的证据推荐在子宫肌瘤管理中使用任何药物治疗。然而,某些治疗方法具有未来前景,不过需要进一步设计良好的RCT。